158144-85-5

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 4-(HYDROXYMETHYL)-4-PHENYLPIPERIDINE-1-CARBOXYLATE is used as a building block for the synthesis of more complex compounds, particularly in the development of new pharmaceuticals. Its unique structure, which includes a phenyl group, a tert-butyl ester group, a hydroxymethyl group, and a carboxylate group, allows for versatile chemical reactions and modifications, making it a valuable component in the creation of novel drug molecules. TERT-BUTYL 4-(HYDROXYMETHYL)-4-PHENYLPIPERIDINE-1-CARBOXYLATE's potential applications in this industry are vast, as it can be tailored to target specific therapeutic areas or to improve the properties of existing medications.

Upstream product

• 3627-45-0 4-phenyl-piperidine-4-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 167262-68-2 N-(t-butyloxycarbonyl)-4-phenylpiperidine-4-carboxylic acid 
• 34619-03-9 tert-butyldicarbonate 
• 4220-08-0 (4-phenyl-piperidin-4-yl)-methanol 

Downstream Products

• 1026630-76-1 4-(3,5-Dimethyl-benzyloxymethyl)-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester 
• 1026458-87-6 4-(3,5-Dichloro-benzyloxymethyl)-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester 
• 1026598-13-9 4-Phenyl-4-(3-trifluoromethyl-benzyloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1100215-48-2 (+/-)-tert-Butyl 4-phenyl-4-((1-(5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)ethoxy)methyl)piperidine-1-carboxylate 
• 1100212-53-0 tert-butyl 4-(((7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)methoxy)methyl)-4-phenylpiperidine-1-carboxylate 
• 1100213-09-9 tert-butyl 4-(((5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-7-yl)methoxy)methyl)-4-phenylpiperidine-1-carboxylate 
• 1100212-56-3 tert-butyl 4-(((5-bromo-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-7-yl)methoxy)methyl)-4-phenylpiperidine-1-carboxylate 
• 1100212-72-3 tert-butyl 4-phenyl-4-(((5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-7-yl)methoxy)methyl)piperidine-1-carboxylate 
• 1100212-91-6 (+/-)-tert-Butyl 4-phenyl-4-((1-(5-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-7-yl)ethoxy)methyl)piperidine-1-carboxylate 
• 1100213-19-1 tert-butyl 4-(((3-bromo-5-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-7-yl)methoxy)methyl)-4-phenylpiperidine-1-carboxylate 
• 1100213-36-2 (+/-)-tert-butyl 4-((1-(5-chloro-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-7-yl)ethoxy)methyl)-4-phenylpiperidine-1-carboxylate 
• 1100213-48-6 (+/-)-tert-butyl 4-((1-(3-bromo-5-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-7-yl)ethoxy)methyl)-4-phenylpiperidine-1-carboxylate 
• 1100215-42-6 tert-butyl 4-phenyl-4-((((5-(trifluoromethyl)-1-((2-trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)methoxy)methyl)piperidine-1-carboxylate 
• 1100215-65-3 tert-butyl 4-phenyl-4-(((6-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-4-yl)methoxy)methyl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

Biaryls as potent, tunable dual neurokinin 1 receptor antagonists and serotonin transporter inhibitors

Depression is a serious illness that affects millions of patients. Current treatments are associated with a number of undesirable side effects. Neurokinin 1 receptor (NK1R) antagonists have recently been shown to potentiate the antidepressant e

Substituted Heterocyclic Ethers and Their Use in CNS Disorders

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.

SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.

SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.

NK-1 AND SEROTONIN TRANSPORTER INHIBITORS

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.

OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF

The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment or prevention of a condition selected from obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.

INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention can provide a cancer treatment drug containing, as an active ingredient, a substance selected from the group consisting of an indazole compound of the following formula (I), a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate:

1-AMIDO-4-PHENYL-4-BENZYLOXYMETHYL-PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROKININ-1(NK-1) ANTAGONISTS FOR THE TREATMENT OF EMESIS, DEPRESSION, ANXIETY AND COUGH

Disclosed are NK1 antagonists having the formula: Also disclosed are uses of compounds of formula (I) for the manufacture of a medicament for treating a number of physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

Substituted piperidines as melanocortin-4 receptor agonists

Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Also provided are methods of treating sexual dysfunction with a compound that is a selective agonist of MC-4R over any other human melanocortin receptor.